Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Access And Affordability Are Key, Says New EMA Head

Emer Cooke Says She'll Be A Very Different Kind Of Leader

Executive Summary

Ensuring patients have access to approved medicines is a key priority for Emer Cooke, the soon-to-be new head of the European Medicines Agency. Cooke says she will probably be a very different type of “captain” of the “wonderful ship” that is the EMA.

You may also be interested in...



New Powers For EMA Under EU ‘Future Proofing’ Plans

A new legislative proposal is seeking to empower the European Medicines Agency in tracking potential shortages of drugs and medical devices and enable the agency to play a greater role in coordinating clinical trials and vaccine research during health emergencies.

‘Unprecedented’ EMA Response To COVID-19 Must Be Sustained

The agility, flexibility and transparency that the European Medicines Agency has adopted during the development and assessment of COVID-19 products will have to continue after treatments and vaccines are on the market, says the soon-to-be new head of the agency, Emer Cooke.

Outlook To Make Its Case For Ophthalmic Bevacizumab At High-Stakes EMA Meeting

Outlook Therapeutics is hoping to secure EU marketing approval for the first ophthalmic formulation of bevacizumab.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel